Skip to main content
INVION LIMITED logo

INVION LIMITED — Investor Relations & Filings

Ticker · IVX ISIN · AU000000IVX4 LEI · 529900JY0HVEQEMSSJ32 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,119 across all filing types
Latest filing 2019-05-27 Capital/Financing Update
Country AU Australia
Listing ASX IVX

About INVION LIMITED

https://inviongroup.com

Invion Limited is a life sciences company dedicated to the development and commercialization of Photosoft technology, a next-generation Photodynamic Therapy (PDT). The company focuses on utilizing this light-activated treatment platform to target various forms of cancer and infectious diseases. Photosoft technology is derived from natural chlorophyll and is designed to selectively destroy malignant cells while minimizing damage to healthy tissue. Invion's research and development efforts are primarily directed toward oncology applications, including the treatment of skin, lung, and ovarian cancers, as well as addressing global health challenges through the treatment of viral and bacterial infections. The company aims to provide non-invasive or minimally invasive therapeutic alternatives that offer improved patient outcomes and reduced side effects compared to conventional treatment modalities.

Recent filings

Filing Released Lang Actions
Animal studies show IVX-P02 potential in metastatic cancers 2 pages 89.2KB
Capital/Financing Update Classification · 85% confidence The document is a press release from Invion Limited announcing the completion of initial in vivo animal studies on their cancer drug candidate IVX-P02. It highlights experimental results and potential future clinical trials but does not contain financial data, regulatory filings, or detailed financial reports. There is no indication that this is an earnings release, annual or interim report, or any formal regulatory filing. The content is primarily an update on research progress and scientific findings, typical of a Capital/Financing Update or general company announcement. Given the focus on research progress and potential clinical trials, and absence of financial results or governance information, the best fitting category is Capital/Financing Update (CAP).
2019-05-27 English
Appendix 4C - March 2019 quarter 5 pages 22.1KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Appendix 4C Quarterly report for entities subject to Listing Rule 4.7B' and contains detailed consolidated cash flow statements for the quarter ended 31 March 2019. It includes financial data such as cash flows from operating, investing, and financing activities, payments to directors, and estimated cash outflows for the next quarter. The document also includes a compliance statement confirming preparation in accordance with accounting standards and Listing Rule 19.11A. The presence of substantive financial data for a quarter and the quarterly period reference clearly indicate this is a quarterly financial report. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). Q3 2019
2019-04-17 English
Quarterly Update 2 pages 85.6KB
Capital/Financing Update Classification · 85% confidence The document is an ASX announcement titled 'QUARTERLY UPDATE' and discusses financial and operational updates for the quarter ending 31 March 2019. It mentions the lodging of Appendix 4C, which is a quarterly cash flow report commonly used in Australian markets. The content includes financial figures, trial progress, and future expectations, but it is relatively short (3484 characters) and primarily serves as an update rather than a comprehensive financial report. It does not contain detailed financial statements or substantive financial data typical of an Interim/Quarterly Report (IR). Instead, it fits the profile of a Capital/Financing Update (CAP) as it discusses funding, R&D income, and financial arrangements related to the company's operations and trials. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2019-04-17 English
Response to ASX Price Query 3 pages 446.7KB
Regulatory Filings Classification · 95% confidence The document is a letter from ASX Compliance to Invion Limited requesting information about unusual trading activity in the company's securities, and the company's response to that query. It references compliance with ASX Listing Rules, particularly Listing Rule 3.1 regarding continuous disclosure obligations. The content is a regulatory inquiry and response about market disclosure and trading behavior, not a financial report, earnings release, or other corporate filing. It is a regulatory filing related to compliance and market disclosure rather than a report or announcement of financial results or corporate actions. The document length is 7,822 characters, which is relatively short and focused on regulatory compliance. Therefore, the appropriate classification is Regulatory Filings (RNS).
2019-03-31 English
Corporate Update and Investor Presentation - Q1 2019 35 pages 2.5MB
Regulatory Filings
2019-02-27 English
Corporate update to support BD and investor meetings 1
Investor Presentation Classification · 95% confidence The document is an updated non-confidential presentation released by Invion Limited to support CEO meetings starting March 2019. It outlines the clinical strategy and forward focus of the company, intended for meetings with brokers, investment bankers, and potential investors. The content is consistent with an investor presentation rather than a formal report or regulatory filing. The document length is short (2002 characters), but it contains substantive presentation content rather than just an announcement or a link to a report. Therefore, it fits the category of an Investor Presentation (IP).
2019-02-27 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.